NCT02650167 (COLOSTRUM) is a NA clinical trial of Colostrum feeding in Infant, Premature, sponsored by Centre Hospitalier Universitaire de Nice.

Who is sponsoring NCT02650167?

NCT02650167 is sponsored by Centre Hospitalier Universitaire de Nice.

What drugs are being tested in NCT02650167?

Interventions in NCT02650167: Colostrum feeding, formula for preterm infants.

What condition does NCT02650167 study?

NCT02650167 studies Infant, Premature.

Is NCT02650167 still recruiting?

NCT02650167 is currently completed. Last updated 30 September 2020.

Last reviewed 2020-09-30 · How we verify

NCT02650167: COLOSTRUM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea

Completed NA Last updated 30 September 2020

What this trial tests

NA trial testing Colostrum feeding in Infant, Premature in 140 participants. Completed in 24 September 2020.

Timeline

27 April 2016

Primary endpoint
5 May 2018

24 September 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	140
Start date	27 April 2016
Primary completion	5 May 2018
Estimated completion	24 September 2020
Sites	1 location across France

Drugs / interventions tested

Colostrum feeding — full drug profile →
formula for preterm infants — full drug profile →

Conditions studied

Infant, Premature — all drugs for Infant, Premature →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Eligibility, any sex, with Infant, Premature. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Colostrum is the first milk secreted by the mother when the tight junctions of mammary epithelium open, allowing the cellular transport of a multitude of components and immunological protective derivatives of the maternal circulation to the milk, and especially immunoglobulins A type. Colostrum is not given to preterm neonates. The assumption behind this work is that the oro pharyngeal administration of colostrum early in preterm infants could help deliver an oral immunotherapy even before the installation of enteral nutrition, through interactions with lymphoid tissues of the oropharynx and the gastrointestinal tract. This practice would improve the digestive tolerance and the establishment of enteral feeding, the decrease in mucosal inflammatory phenomena, but also to provide any protection against subsequent infections. Finally, there could be an improvement in the secondary immune tolerance with a decrease in the occurrence of allergic phenomena.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oropharyngeal Colostrum for Preterm Infants: A Systematic Review and Meta-Analysis.
Panchal H, Athalye-Jape G, Patole S. · · 2019 · cited 28× · PMID 31147686 · DOI 10.1093/advances/nmz033

Verify or expand the search:

Other recruiting trials for Infant, Premature

Currently open trials in the same condition.

NCT07045402 — Effect of Developmental Care on Comfort, Growth, and Oral Feeding Transition in Preterm Infants · NA · recruiting
NCT06726226 — Extremely Preterm Respiratory Outcome Cohort · recruiting
NCT03456336 — Management of the PDA Trial · Phase 3 · active not recruiting
NCT02738411 — Influence of Intestinal Microbiota Implantation in Preterm Infants on Microbiota and Immune Orientation at 3 Years · active not recruiting
NCT00009633 — Follow-up Visit of High Risk Infants · recruiting

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02650167 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
Last refreshed: 30 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02650167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing